P4 M01
Alternative Names: P4-M01Latest Information Update: 03 Nov 2025
At a glance
- Originator P4 Microbiome
- Developer D and D Pharmatech; P4 Microbiome
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Periodontal disorders
- Preclinical Inflammatory bowel diseases; Intestinal infections
Most Recent Events
- 03 Nov 2025 Preclinical development is ongoing in South Korea (P4 Microbiome pipleline, November 2025)
- 26 Dec 2022 Preclinical trials in Intestinal infections in South Korea (unspecified route), prior to December 2022 (P4 Microbiome pipeline, December 2022)
- 26 Dec 2022 P4 M01 is still in phase II trials for Periodontal disorders (D and D Pharmatech pipeline, December 2022)